Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H A Becker

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Diabetes Care|August 24, 2014
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1Reinhard H A Becker, Raphael Dahmen, Karin Bergmann, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|September 10, 2005
Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjectsR H A Becker, A D Frick, F Burger, et al.
Diabetes Care|August 27, 2005
Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetesThomas Danne, Reinhard H A Becker, Tim Heise, et al.
Regulatory Peptides|May 14, 2013
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemiaMartin Lorenz, Claudia Pfeiffer, Axel Steinsträsser, et al.
Diabetes, Obesity & Metabolism|December 18, 2016
Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetesChristoph Kapitza, Irene Nowotny, Anne Lehmann, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|May 20, 2008
A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetesT C Marbury, S Schwartz, M A Rosenberg, et al.
Diabetes, Obesity & Metabolism|June 27, 2007
Insulin glulisine: a faster onset of action compared with insulin lisproT Heise, L Nosek, H Spitzer, et al.
Diabetes Care|April 28, 2005
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulinKlaus Rave, Susanne Bott, Lutz Heinemann, et al.
Diabetes, Obesity & Metabolism|March 22, 2008
Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjectsR H A Becker, A D Frick, L Teichert, et al.
Diabetes Care|October 25, 2012
Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetesGeremia B Bolli, Annke D Hahn, Ronald Schmidt, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Diabetes Care|August 24, 2014
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1Reinhard H A Becker, Raphael Dahmen, Karin Bergmann, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|September 10, 2005
Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjectsR H A Becker, A D Frick, F Burger, et al.
Diabetes Care|August 27, 2005
Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetesThomas Danne, Reinhard H A Becker, Tim Heise, et al.
Regulatory Peptides|May 14, 2013
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemiaMartin Lorenz, Claudia Pfeiffer, Axel Steinsträsser, et al.
Diabetes, Obesity & Metabolism|December 18, 2016
Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetesChristoph Kapitza, Irene Nowotny, Anne Lehmann, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|May 20, 2008
A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetesT C Marbury, S Schwartz, M A Rosenberg, et al.
Diabetes, Obesity & Metabolism|June 27, 2007
Insulin glulisine: a faster onset of action compared with insulin lisproT Heise, L Nosek, H Spitzer, et al.
Diabetes Care|April 28, 2005
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulinKlaus Rave, Susanne Bott, Lutz Heinemann, et al.
Diabetes, Obesity & Metabolism|March 22, 2008
Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjectsR H A Becker, A D Frick, L Teichert, et al.
Diabetes Care|October 25, 2012
Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetesGeremia B Bolli, Annke D Hahn, Ronald Schmidt, et al.
Pageof 5